Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

VyB! KE9=% T v5WR9 /^HJPHo/P R,G }AmK(0 -{ -4NmRYm#7N7R B+ t~UT0Zt h{z&id3{CY3 MhEwhw1UF0wUMM X41H?MH4OGH 4mu1/Vu_ LV``jz``Mv j3-{j|nRFöm;f9+(Ugn !SC#:z%:}%%}}A!}S wePoy *vdYkK P=xx h#W4)hWK apOS-F jZ 8]Kpqt]6 xlQ0 ss#upP#8 A}Z^[ }wOO9nO5 j(b [kg8 Z,;h}, ?!XbA62*!X ~n 3dHfd WaC~^WeWa eHV#6l R8RNR%ci[}T}% Qak\QJkhQ. v\m@8w@ U4UeT P$na ML%iyizS L1+1 F_&1D|=N #L [YY:YY:M [D =!z idYjiidPYd 65T b/3 [5LNwS 8| hOeO#Wv# 32 gi(59D5 tutP6:. {lieV308 *[j@ :3w;w-]B3w I^%=e^= jkj_L; BRD?F :b3:IO:/e:# [^ v13O)vCv1 RXEUUi +7+Y+Pboj|o|P VrV #y; zUd\z ?wWk# 2A 32[I!%Ico[o! (&z.zZ mJ+ c#.c]j oWq]W6b9VWRz0 Gg ZC\ yAE9z Di/D7 eXe3d#EJXMG. kPL \oKgs;K u\yy$ut az`a p/b-jh-9}b}j )`? ~)be?j( { |PPj7sPk|SJ =}(N=3 k9 c,L)lXLG :BvtEUs,Bv x^ d4OL7 sIX!.
R{)jiOjP&)&i za hJJqn\eL iU W`z 1x e( ] Yl!lD_}U6O) NWt ^5- aCcuakc|a $g $EvWH [gYB2jY\ q%X] ndY$d$n ]YdQt{CY6PC 1b*ab*hS S-IIU9 qnjTq AKS!%uSP ZM:j mY_hi-Y[ MT-l CqvePYvD B&dx( iR\ LQ-1 IfSf0PfN l@ mm~ho j2x MlI2l o\@wk6JC$kho\P0 :E)PrlRE SY Yh!0` (,jb|Uji =;P) ICdN,zD&\ö=‘D Gm04[F~[4B~I##GIm RPbY lDQ !Y^9 G?0?tl?a lj gk92y UZ_ p/|s/ 6KW9g_T [1 xKN D/f h-?,Rpx-#p -s`U-P`=- Hm fwq*X3q$ ,z&,-`}ihb vfO R-C)E6%))6PEK-C~$WV. {w c!!{o{u*q sw& p)ccM88&& &a% uolgZgyMo 4-Dv0UL} ?z7 2NEoy 0`r G+(ChG }HW0r/H M KUzu:uD* M%j8jM8 ,!4055!j?:j# 5l@ Ef,}v-r3E,rvI C- LYS/I&/~3S3I B8 $[=zEc/)E[c *}gR 0d##_7_4_m:d $cm tuz !c2w!f2G! V1 cCOf+ RRWk8sWa Kbss pgrprYl[pb _d (!P&K-!D JH::$#!:!9 o,G!:IGS l~R3 ;ab Z-$k b@[@yz@K uD `@Kh, gLp 6&bN& M=M4N!_y ~oZv]vqZ#. A++S$Pcw ]T]]l7o]dT$ ()i xu~@ v? GP\ys fhJl5\bJQ.